Marblehead, MA, United States of America

Torsten Woehr

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Other. Active years: 2015.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,411 
Other
 patents

Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Torsten Woehr

Introduction

Torsten Woehr is an accomplished inventor based in Marblehead, MA (US). He has made significant contributions to the field of pharmaceutical formulations, particularly in the area of controlled-release peptide formulations. His innovative work has led to advancements in drug delivery systems, enhancing the efficacy of bioactive agents.

Latest Patents

Woehr holds a patent for "Controlled-released peptide formulations." This patent describes methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems. The innovation focuses on direct modification of the isoelectric point and/or net charge of the bioactive agent, which is crucial for improving drug delivery.

Career Highlights

Throughout his career, Torsten Woehr has worked with notable companies, including Genzyme Corporation. His experience in the pharmaceutical industry has allowed him to develop and refine his expertise in drug delivery technologies.

Collaborations

Woehr has collaborated with professionals such as Kevin Burton and Thomas R Tice. These partnerships have contributed to his innovative approaches and successful projects in the field.

Conclusion

Torsten Woehr's contributions to controlled-release peptide formulations exemplify the impact of innovation in drug delivery systems. His work continues to influence advancements in the pharmaceutical industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…